Halozyme Therapeutics(FRA) RV7

Market Cap€10.38B

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

€90.66

-0.74%

-0.68Today

Halozyme Therapeutics Financials at a Glance

Market Cap

€10.38B

Revenue (TTM)

€1.43K

Net Income (TTM)

€354.29

EPS (TTM)

€2.87

P/E Ratio

31.91

Dividend

€0.00

Beta (Volatility)

0.06 (Low)

Dividend

€0.00

Beta (Volatility)

0.06 (Low)

Price

€90.66

Volume

Open

€90.66

Price

€90.66

Volume

Open

€90.66

Previous Close

€90.66

Daily Range

€90.66 - €90.66

52-Week Range

€52.50 - €93.36

Estimated Earnings Date

N/A

Dividend

€0.00

Beta (Volatility)

0.06 (Low)

Price

€90.66

Volume

Open

€90.66

Previous Close

€90.66

Daily Range

€90.66 - €90.66

52-Week Range

€52.50 - €93.36

Estimated Earnings Date

N/A

RV7 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Industry

Biotechnology

Sector

Health Care

Employees

423

CEO

Helen I. Torley, MD

Website

www.halozyme.com

RV7 Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

173.24%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

3.13%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€10.38B

Shares Outstanding

113.50M

Volume

Avg. Volume

95.864

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Halozyme Therapeutics Performance Analysis

Halozyme Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 628,099,079	67.5%
2023	2023-12-31	EUR 767,034,531	22.1%
2024	2024-12-31	EUR 938,645,351	22.4%
2025	2025-12-31	EUR 1,237,496,266	31.8%

Halozyme Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR 1.37	-41.1%
2023	2023-12-31	EUR 1.94	41.9%
2024	2024-12-31	EUR 3.17	63.4%
2025	2025-12-31	EUR 2.27	-28.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

€413.69

+1.4%

Gross Profit

€320.21

+1.4%

Gross Margin

77.40%

+1.0%

Market Cap

€10.38B

N/A

Market Cap/Employee

€19.06

N/A

Employees

423

N/A

Net Income

€197.74

+1.4%

EBITDA

€276.65

+1.4%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

€2.02K

+51.0%

Total Debt

€1.88K

+1.5%

Accounts Receivable

€398.69

+1.5%

Inventory

€119.95

+0.8%

Long Term Debt

€1.69K

+1.3%

Short Term Debt

€182.78

N/A

Return on Assets

17.70%

+0.6%

Return on Invested Capital

21.37%

+0.6%

Free Cash Flow

€204.53

+2.7%

Operating Cash Flow

€208.14

+2.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About RV7

What is the current price of Halozyme Therapeutics?

Halozyme Therapeutics is trading at €90.66 per share.

What is the 52-week range for Halozyme Therapeutics?

Over the past 52 weeks, Halozyme Therapeutics has traded between €52.50 and €93.36.

How much debt does Halozyme Therapeutics have?

As of the most recent reporting period, Halozyme Therapeutics reported total debt of €1.88B.

How much cash does Halozyme Therapeutics have on hand?

Halozyme Therapeutics reported €142.69M in cash and cash equivalents in its most recent financial results.

What is Halozyme Therapeutics’s dividend yield?

Halozyme Therapeutics does not currently have a dividend yield.

Halozyme Therapeutics(FRA) RV7

Halozyme Therapeutics Financials at a Glance

RV7 News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Halozyme Therapeutics

RV7 Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Halozyme Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About RV7

What is the current price of Halozyme Therapeutics?

What is the 52-week range for Halozyme Therapeutics?

How much debt does Halozyme Therapeutics have?

How much cash does Halozyme Therapeutics have on hand?

What is Halozyme Therapeutics’s dividend yield?

Premium Investing Services